NCT03335332 is a NA clinical trial of High intensity exercise in Hypertrophic Cardiomyopathy, sponsored by University of Texas Southwestern Medical Center.

Who is sponsoring NCT03335332?

NCT03335332 is sponsored by University of Texas Southwestern Medical Center.

What drugs are being tested in NCT03335332?

Interventions in NCT03335332: High intensity exercise, Moderate intensity exercise.

What condition does NCT03335332 study?

NCT03335332 studies Hypertrophic Cardiomyopathy.

Is NCT03335332 still recruiting?

NCT03335332 is currently completed. Last updated 28 February 2023.

Last reviewed 2023-02-28 · How we verify

NCT03335332

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

High Intensity Exercise for Increasing Fitness in Patients With Hypertrophic Cardiomyopathy

Completed NA Last updated 28 February 2023

What this trial tests

NA trial testing High intensity exercise in Hypertrophic Cardiomyopathy in 29 participants. Completed in 20 December 2022.

Timeline

31 January 2018

Primary endpoint
26 July 2022

20 December 2022

Quick facts

Lead sponsor	University of Texas Southwestern Medical Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	29
Start date	31 January 2018
Primary completion	26 July 2022
Estimated completion	20 December 2022
Sites	1 location across United States

Drugs / interventions tested

High intensity exercise
Moderate intensity exercise

Conditions studied

Hypertrophic Cardiomyopathy — all drugs for Hypertrophic Cardiomyopathy →

Sponsor

University of Texas Southwestern Medical Center

Who can join

Adults 18 to 80, any sex, with Hypertrophic Cardiomyopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Although current clinical guidelines stipulate that patients with hypertrophic cardiomyopathy should not partake in high intensity exercise (HIE) or competitive sport due to safety concerns, there is no clear evidence to support this notion. In fact, two exercise training interventions in this population indicates that regular moderate to vigorous intensity exercise is efficacious for improving exercise capacity and cardiorespiratory fitness, and does not increase arrhythmia burden or adverse events. Moreover, moderate intensity exercise and HIE training significantly increases cardiorespiratory fitness in patients with cardiac disease. Such improvements are associated with substantial reductions in cardiovascular mortality and might outweigh the risk of adverse events in patients with hypertrophic cardiomyopathy (HCM). Having a genetic cardiomyopathy does not grant immunity against lifestyle related cardiometabolic diseases and inactivity is rife in HCM patients likely due to misinformation/education. It is therefore paramount to further explore the benefits of regular moderate intensity exercise and HIE in patients with HCM for proper therapeutic management of the condition.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Randomized Controlled Trial of Moderate- and High-Intensity Exercise Training in Patients With Hypertrophic Cardiomyopathy: Effects on Fitness and Cardiovascular Response to Exercise.
MacNamara JP, Dias KA, Hearon CM, Ivey E, et al · · 2023 · cited 28× · PMID 37830338 · DOI 10.1161/jaha.123.031399
Hypertrophic Cardiomyopathy: Updates Through the Lens of Sports Cardiology.
Lander BS, Phelan DM, Martinez MW, Dineen EH. · · 2021 · cited 6× · PMID 34054288 · DOI 10.1007/s11936-021-00934-1
Impaired longitudinal systolic-diastolic coupling and cardiac response to exercise in patients with hypertrophic cardiomyopathy.
MacNamara JP, Turlington WM, Dias KA, Hearon CM, et al · · 2024 · cited 4× · PMID 38895911 · DOI 10.1111/echo.15857

Verify or expand the search:

Other trials of High intensity exercise

Trials testing the same drug.

NCT07375420 — Will a Pre-therapy Exercise Intervention Improve the Outcomes of Patients With Advanced Oesophageal Cancer? · NA · recruiting
NCT05777564 — Tolerability of High Intensity Exercise for Knee Osteoarthritis · NA · completed
NCT05745922 — Acute Effects of Endurance Exercise on Breast Milk Composition in Women With Overweight/Obesity · NA · completed
NCT05768165 — High-intensity Interval Exercise in Rheumatoid Arthritis · NA · active not recruiting
NCT04806152 — Sarcopenia and Combined-modality Exercise · NA · terminated

Other recruiting trials for Hypertrophic Cardiomyopathy

Currently open trials in the same condition.

NCT07361289 — A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopa · recruiting
NCT06490250 — Comparison of the Effects of Inspiratory Muscle Training and Baduanjin Exercises in Hypertrophic Cardiomyopathy Patients · NA · recruiting
NCT06573723 — Institutional Registry of Rare Diseases · recruiting
NCT06549608 — A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada · active not recruiting
NCT05939700 — Mavacamten Pregnancy Surveillance Program · recruiting

Other University of Texas Southwestern Medical Center trials

Trials by the same sponsor.

NCT03849963 — Imaging Oxidative Metabolism and Neurotransmitter Synthesis in the Human Brain · recruiting
NCT06917183 — Developing Strategies for Implementation and Use of the Operating Room Black Box (ORBB) · NA · not yet recruiting
NCT05145309 — Value of Potassium Magnesium Citrate in Preventing and Treating Hypertension in African Americans · Phase 2 · not yet recruiting
NCT06552000 — Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer · NA · not yet recruiting
NCT07387666 — Imaging Acetadote Metabolism in Glioblastoma · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03335332 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Texas Southwestern Medical Center
Last refreshed: 28 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03335332.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing